MiNK Therapeutics reports favorable lung immune data for cell therapy candidate
MiNK Therapeutics (NASDAQ:INKT) disclosed new clinical and translational data demonstrating that its off-the-shelf allogeneic cell therapy, agenT-797, successfully induced localized tissue repair and pathogen clearance when administered to a critically ill pulmonary patient.
The clinical findings were presented at the American Thoracic Society (ATS) 2026 International Conference and published concurrently in Clinical Immunology Communications.
The single-patient data mapped the therapeutic impact of sequential immunotherapy using ImmunityBio’s FDA-approved interleukin-15 superagonist, Anktiva (N-803), followed by infusions of MiNK’s unmodified invariant natural killer T (iNKT) cell candidate, agenT-797.
The patient presented with a high-acuity combination of unresolving, disseminated Coccidioides immitis (valley fever), acute respiratory distress syndrome (ARDS), and a concurrent hospital-acquired Pseudomonas aeruginosa pneumonia infection.
Translational tracking from the case demonstrated clear biological activity within the microenvironment of the lung.
Following biological dosing, investigators recorded a measurable suppression of both the underlying fungal and bacterial pathogens.
This clearance was accompanied by the recruitment of active immune cells into the respiratory tissue, a down-regulation of hyperinflammatory signaling cascades, and the direct activation of localized tissue repair pathways.
The mechanism matches broader dataset outcomes presented by the company earlier in the month, which indicated that the same donor-derived batch of unmodified iNKT cells can selectively deploy an anti-inflammatory Th2 response in injured lung tissues while executing a pro-inflammatory cytotoxic program when evaluated in oncology environments.
The supportive case observations arrive as the New York-based biopharmaceutical firm shifts into advanced clinical evaluation for the program.
MiNK has formally initiated a randomized Phase 2 clinical trial evaluating the off-the-shelf, cryopreserved candidate plus standard medical care compared directly against a placebo regimen in adults experiencing severe acute lung injury and high-acuity critical illness.
The multi-center study targets intensive care unit patients suffering from moderate-to-severe acute hypoxemic respiratory failure who meet global clinical ARDS criteria.
Because agenT-797 is engineered to be administered rapidly without requiring human leukocyte antigen (HLA) tissue matching or lymphodepleting chemotherapy preparation, management expects the trial pipeline to advance efficiently.
Preliminary readouts from the randomized Phase 2 cohorts are anticipated during the second half of calendar year 2026.
